オカノ テルオ
Okano Teruo
岡野 光夫 所属 医学研究科 医学研究科 (医学部医学科をご参照ください) 職種 評議員 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Engineering liver tissues under the kidney capsule site provides therapeutic effects to hemophilia B mice. |
掲載誌名 | 正式名:Cell transplantation 略 称:Cell Transplant ISSNコード:(1555-3892)0963-6897(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 19(6),pp.807-13 |
著者・共著者 | Ohashi Kazuo†*, Tatsumi Kohei, Utoh Rie, Takagi Soichi, Shima Midori, Okano Teruo |
担当区分 | 最終著者 |
発行年月 | 2010/06 |
概要 | Recent advances in liver tissue engineering have encouraged further investigation into the evaluation of therapeutic benefits based on animal disease models. In the present study, liver tissues were engineered in coagulation factor IX knockout (FIX-KO) mice, a mouse model of hemophilia B, to determine if the tissue engineering approach would provide therapeutic benefits. Primary hepatocytes were isolated from the liver of wild-type mice and suspended in a mixture of culture medium and extracellular matrix components. The hepatocyte suspension was injected into the space under the bilateral kidney capsules of the FIX-KO mice to engineer liver tissues. The plasma FIX activities (FIX:C) of the untreated FIX-KO mice were undetectable at any time point. In contrast, the liver tissue engineered FIX-KO mice achieved 1.5-2.5% of plasma FIX activities (FIX:C) and this elevated FIX:C level persisted throughout the 90 day experimental period. Significant FIX mRNA expression levels were found in the engineered liver tissues at levels similar to the wild-type livers. The present study demonstrates that liver tissue engineering could provide therapeutic benefits in the treatment of hemophilia B. |
DOI | 10.3727/096368910X508924 |
PMID | 20573301 |